AZN · story · 14 October – 17 October

Analysts update AstraZeneca ratings and targets

AstraZeneca · 14 headlines from 8 outlets, from 14 October 2026 to 17 October 2026.

+7.1strongly positive

+7.1

Headlines14

Outlets8

Days414 October – 17 October

Citi raised its target and Deutsche Bank reiterated Neutral, with other pieces noting bullish targets amid oncology deals.

Tone by day

Average of each day's headlines, −10 to +10.

Source: MarketFrame news analysis

Tone by day. Average of each day's headlines, −10 to +10. Source: MarketFrame news analysis
day	Average tone
14 Oct	6.0
15 Oct	7.4
16 Oct	7.3
17 Oct	6.9

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Every outlet, by impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

Every outlet, by impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outlet	Average tone
AD HOC NEWS	6.4
StocksToTrade	9.3
Timothy Sykes	8.8
Moomoo	7.3
Yahoo Finance	8.3
Pluang	7.5
MarketScreener	3.5
Proactive financial news	7.0

Outlet	Headlines	Average tone
AD HOC NEWS	3	+6.4
StocksToTrade	2	+9.3
Timothy Sykes	2	+8.8
Moomoo	2	+7.3
Yahoo Finance	1	+8.3
Pluang	1	+7.5
MarketScreener	2	+3.5
Proactive financial news	1	+7.0

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Tone	What the article reported, and why it scored that way	Source
+8.3	Citi raises price target to £186.	Yahoo Finance (opens the article) ↗
+6.7	Berenberg keeps Buy rating.	MarketScreener (opens the article) ↗
+5.8	RBC maintains high price target.	AD HOC NEWS (opens the article) ↗

AstraZeneca on 17 October

Tone	What the article reported, and why it scored that way	Source
+7.5	UBS maintains Buy rating with high target.	Moomoo (opens the article) ↗
+7.5	RBC keeps outperform, expects strong trial data.	Pluang (opens the article) ↗
+7.0	RBC outperform ahead of lung cancer trial.	Proactive financial news (opens the article) ↗

AstraZeneca on 16 October

Tone	What the article reported, and why it scored that way	Source
+9.3	Upgrades arrive while oncology dealmaking speeds up	StocksToTrade (opens the article) ↗
+9.2	Optimistic price targets arrive with a growing number of oncology deals	StocksToTrade (opens the article) ↗
+8.8	Bullish targets on oncology deals	Timothy Sykes (opens the article) ↗
+8.7	Stock gains favour on oncology deals	Timothy Sykes (opens the article) ↗
+8.3	Citi raised price target	AD HOC NEWS (opens the article) ↗
+0.3	Neutral rating reiterated	MarketScreener (opens the article) ↗

AstraZeneca on 15 October

Tone	What the article reported, and why it scored that way	Source
+7.0	Barclays maintains Buy rating and target.	Moomoo (opens the article) ↗
+5.0	Jefferies keeps a high price target.	AD HOC NEWS (opens the article) ↗

AstraZeneca on 14 October

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

Analysts update AstraZeneca ratings and targets

The story

Tone by day

How each outlet covered it · 8 outlets

Every outlet, by impact on the tone

Day by day · 4 days, strongest headlines first

Follow by email